1989 Vaccine Schedule: Vaccines, Timing, and the NVICP

The 1989 childhood vaccine schedule in the United States called for four vaccines protecting against eight diseases: diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, and Haemophilus influenzae type b (Hib). A child who followed the recommendations received about 11 to 12 doses between two months of age and school entry, plus a tetanus-diphtheria booster in adolescence.

The Four Vaccines and What They Covered

Each shot on the 1989 schedule targeted diseases that were deadly, highly contagious, or both.

DTP was a three-in-one shot against diphtheria, tetanus, and pertussis. Diphtheria is a bacterial throat infection that can produce a thick membrane blocking the airway. Tetanus (lockjaw) causes severe muscle spasms triggered by a toxin from bacteria that enter through wounds. Pertussis (whooping cough) is a highly contagious respiratory illness especially dangerous to infants. The 1989 DTP used whole, inactivated pertussis bacteria — effective, but with a rougher side-effect profile than the acellular version that later replaced it.

OPV, the oral polio vaccine, used a live, weakened virus given as liquid drops by mouth. It had been the U.S. standard since the early 1960s, valued for easy administration and strong intestinal immunity that helped limit community spread.¹ The tradeoff was a very small risk of vaccine-associated paralytic polio, estimated at roughly one case per 2.6 million doses distributed overall, with a higher risk of about one case per 520,000 first doses.²

MMR combined protection against measles, mumps, and rubella in a single shot. Measles can cause pneumonia, brain swelling, and death. Mumps causes painful swelling of the salivary glands and can lead to deafness or meningitis. Rubella (German measles) is usually mild in children but devastating to a developing fetus if a pregnant woman becomes infected. In 1989, the Advisory Committee on Immunization Practices added a second dose of MMR to the routine schedule for all children, a response to measles outbreaks then gaining momentum across the country.³

Hib protected against Haemophilus influenzae type b, bacteria that had caused roughly 20,000 cases of serious invasive disease each year in children before vaccination, including about 12,000 cases of meningitis.³ By 1989, conjugate Hib vaccines were recommended for children 15 months and older. One important limit: none of the Hib vaccines available in 1989 were approved for infants. Conjugate vaccines that could be given starting at two months of age were not licensed until late 1990.⁴

The Dose-by-Dose Timing

The 1989 schedule spread vaccinations across infancy, toddlerhood, and school entry. DTP and OPV started early, but their dosing timelines were not identical.

Two months: First DTP and first OPV.
Four months: Second DTP and second OPV.
Six months: Third DTP. OPV did not have a six-month dose; its primary infant series was just two doses.¹
15 months: First MMR. Children 15 months and older also received their Hib conjugate vaccine at this visit or shortly after.¹
15 to 18 months: Fourth DTP and third OPV.¹
4 to 6 years (school entry): Fifth DTP, fourth OPV, and, under ACIP, the second MMR. The American Academy of Pediatrics recommended the second MMR later, at 11 to 12 years, so exact timing depended on which guideline a child’s pediatrician followed.¹
14 to 16 years: First adult-type tetanus-diphtheria (Td) booster, with subsequent Td boosters every 10 years.⁵

A child who followed the full 1989 schedule through school entry received about 11 to 12 total doses, depending on when the second MMR was given.

Why the Schedule Looked This Way in 1989

The second MMR dose was new in 1989, and it was added under pressure. That year the United States saw 17,850 reported measles cases, a 423 percent increase over the 3,411 cases reported the year before. Forty-one people died. Nearly 45 percent of cases occurred in outbreaks among unvaccinated preschool-aged children, concentrated in low-income urban communities in cities like Los Angeles, Chicago, and Houston. Of the 31 children who died, 29 had never been vaccinated.⁶

The resurgence exposed two problems. Many preschoolers in low-income neighborhoods had never received their first MMR at all. And outbreaks were also occurring among school-aged and college-aged populations who had been vaccinated with a single dose, which showed that one shot was not enough for lasting protection in everyone. Adding a routine second MMR dose was the direct answer to that second problem.³

The Hib gap in infancy also shaped the schedule. Because no Hib vaccine approved for infants existed yet, children remained unprotected during the age range when Hib meningitis was most dangerous. That gap closed the following year, when conjugate vaccines licensed for use starting at two months became available.⁴

The Whole-Cell DTP Question

The DTP shot used in 1989 caused more parental anxiety than any other vaccine on the schedule. Its whole-cell pertussis component prevented whooping cough effectively but produced noticeably more reactions than today’s version. Common side effects included redness, swelling, and pain at the injection site, along with fever, drowsiness, irritability, and loss of appetite. More concerning reactions occurred less frequently: febrile and non-febrile seizures at a rate of roughly one per 1,750 doses, and acute encephalopathy at a rate between zero and 10.5 cases per million doses.⁷

Those reactions, combined with a wave of lawsuits against vaccine manufacturers in the 1980s, nearly drove some companies out of the vaccine business. The whole-cell DTP was eventually replaced by DTaP, which uses purified pieces of the pertussis bacterium rather than the whole organism and produces substantially fewer side effects. That transition happened gradually through the 1990s and was complete by 1997.³

The Compensation Program Behind the 1989 Schedule

The legal framework around vaccines had just been rebuilt when the 1989 schedule took effect. The National Childhood Vaccine Injury Act of 1986 created the National Vaccine Injury Compensation Program (VICP), which became operational on October 1, 1988.⁸

The VICP set up a no-fault system for families who believed a child was harmed by a vaccine. Instead of suing a manufacturer directly, a family files a petition with the program. If the claim is denied or the family is unsatisfied with the outcome, a civil lawsuit remains available, but the program must be tried first. That structure gave manufacturers some insulation from litigation while giving families a faster path to compensation than the court system typically offers.⁸

The program is funded by a $0.75 excise tax on each disease a vaccine prevents. A single-disease vaccine like the flu shot carries a $0.75 tax; the MMR, which covers three diseases, carries a $2.25 tax per dose.⁹ The related Vaccine Adverse Event Reporting System (VAERS), a national surveillance tool for tracking potential vaccine side effects, was established shortly after in 1990.¹⁰

How It Compares to Today’s Schedule

The most striking difference is the number of diseases covered. The 2026 childhood schedule protects against 18 diseases, more than double the eight targeted in 1989.¹¹ Vaccines now considered routine that were not on the 1989 schedule include hepatitis B (added universally in 1991), varicella, pneumococcal, hepatitis A, and rotavirus.

Two of the four 1989 vaccines have also been replaced by improved versions. Whole-cell DTP gave way to acellular DTaP. The oral polio vaccine was phased out entirely by the year 2000, replaced by the inactivated polio vaccine (IPV) given as a shot, which eliminates the risk of vaccine-associated paralysis.¹² And the Hib vaccine no longer leaves infants unprotected: conjugate versions approved starting at two months of age closed that gap in late 1990.⁴

1
Centers for Disease Control and Prevention. Recommended Childhood Immunization Schedule – United States, 1995
2
JAMA Network. Vaccine-Associated Paralytic Poliomyelitis: United States: 1973-1984
3
Centers for Disease Control and Prevention. Vaccine-Preventable Diseases, Immunizations, and MMWR – 1961-2011
4
Centers for Disease Control and Prevention. Haemophilus b Conjugate Vaccines for Prevention of Haemophilus influenzae Type b Disease Among Infants and Children Two Months of Age and Older
5
Centers for Disease Control and Prevention. Update on Adult Immunization Recommendations of the Immunization Practices Advisory Committee (ACIP)
6
Centers for Disease Control and Prevention. Current Trends Measles – United States, 1989 and First 20 Weeks of 1990
7
Centers for Disease Control and Prevention. Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among Infants and Young Children – Recommendations of the Advisory Committee on Immunization Practices (ACIP)
8
Office of the Law Revision Counsel. 42 USC Chapter 6A, Subchapter XIX – Vaccines
9
Health Resources and Services Administration. About the National Vaccine Injury Compensation Program
10
VAERS. About VAERS
11
Children’s Hospital of Orange County. American Academy of Pediatrics Releases 2026 Immunization Schedule
12
Centers for Disease Control and Prevention. Polio Vaccination